Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

BACKGROUND: In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy again...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS Negl Trop Dis
Egile Nagusiak: Nguyen, Thi Huyen Tram, Guedj, Jérémie, Anglaret, Xavier, Laouénan, Cédric, Madelain, Vincent, Taburet, Anne-Marie, Baize, Sylvain, Sissoko, Daouda, Pastorino, Boris, Rodallec, Anne, Piorkowski, Géraldine, Carazo, Sara, Conde, Mamoudou N., Gala, Jean-Luc, Bore, Joseph Akoi, Carbonnelle, Caroline, Jacquot, Frédéric, Raoul, Hervé, Malvy, Denis, de Lamballerie, Xavier, Mentré, France
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2017
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340401/
https://ncbi.nlm.nih.gov/pubmed/28231247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0005389
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak